Sun Pharmaceutical Industries Ltd
SUNPHARMASun Pharmaceutical Industries Ltd
SUNPHARMAPrice Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
43.60 | 6.75 | 0.72% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.79 | 6.62 | 0.48% |
Forecast & Ratings
Detailed Forecast from 34 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Sun Pharmaceutical Industries Limited is a pharmaceuticals company which offers generics, branded generics, specialty products, over-the-counter products, anti-retroviral and APIs.
Investor Presentation
View olderPeers
Compare with peersCipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 29,145.28 | 32,201.59 | 27,328.22 | 30,091.40 | 33,489.09 | 34,357.31 | 39,729.96 | 44,520.20 | 49,887.17 | 50,891.06 | ||||||||||
Raw Materials | 6,724.15 | 8,402.37 | 7,193.98 | 8,302.08 | 8,929.60 | 9,328.30 | 10,459.15 | 11,349.07 | 10,370.48 | 36,081.23 | ||||||||||
Power & Fuel Cost | 545.44 | 525.09 | 559.97 | 613.60 | 621.89 | 627.09 | 702.78 | 830.05 | 760.78 | |||||||||||
Employee Cost | 4,772.31 | 4,902.30 | 5,367.05 | 5,967.09 | 6,362.35 | 6,862.23 | 7,300.83 | 8,296.03 | 9,429.06 | |||||||||||
Selling & Administrative Expenses | 5,219.20 | 5,224.61 | 4,727.00 | 5,350.33 | 6,995.37 | 6,283.41 | 7,366.88 | 9,482.36 | 11,033.19 | |||||||||||
Operating & Other expenses | 3,752.78 | 2,434.80 | 3,983.83 | 3,739.60 | 3,214.78 | 6,235.53 | 7,147.91 | 2,452.83 | 4,410.66 | |||||||||||
EBITDA | 8,131.40 | 10,712.42 | 5,496.39 | 6,118.70 | 7,365.10 | 5,020.75 | 6,752.41 | 12,109.86 | 13,883.00 | 14,809.83 | ||||||||||
Depreciation/Amortization | 1,037.53 | 1,264.75 | 1,499.84 | 1,753.25 | 2,052.78 | 2,079.95 | 2,143.74 | 2,529.43 | 2,556.64 | 2,560.45 | ||||||||||
PBIT | 7,093.87 | 9,447.67 | 3,996.55 | 4,365.45 | 5,312.32 | 2,940.80 | 4,608.67 | 9,580.43 | 11,326.36 | 12,249.38 | ||||||||||
Interest & Other Items | 523.24 | 399.80 | 517.57 | 555.25 | 302.73 | 141.43 | 127.35 | 172.00 | 238.47 | 219.13 | ||||||||||
PBT | 6,570.63 | 9,047.87 | 3,478.98 | 3,810.20 | 5,009.59 | 2,799.37 | 4,481.32 | 9,408.43 | 11,087.89 | 12,030.25 | ||||||||||
Taxes & Other Items | 2,024.92 | 2,083.50 | 1,383.28 | 1,144.78 | 1,244.66 | -104.45 | 1,208.59 | 934.85 | 1,511.51 | 1,640.79 | ||||||||||
Net Income | 4,545.71 | 6,964.37 | 2,095.70 | 2,665.42 | 3,764.93 | 2,903.82 | 3,272.73 | 8,473.58 | 9,576.38 | 10,389.46 | ||||||||||
EPS | 20.30 | 28.98 | 8.73 | 11.11 | 15.69 | 12.10 | 13.64 | 35.32 | 39.91 | 43.30 | ||||||||||
DPS | 1.00 | 3.50 | 2.00 | 2.75 | 4.00 | 7.50 | 10.00 | 11.50 | 13.50 | 12.50 | ||||||||||
Payout ratio | 0.05 | 0.12 | 0.23 | 0.25 | 0.25 | 0.62 | 0.73 | 0.33 | 0.34 | 0.29 |
Company Updates
Investor Presentation
Investor Presentation
Annual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Sun Pharmaceutical Industries Ltd | 47.30 | 6.75 | 0.72% |
Cipla Ltd | 31.72 | 4.88 | 0.80% |
Torrent Pharmaceuticals Ltd | 70.36 | 17.00 | 0.81% |
Dr Reddy's Laboratories Ltd | 19.66 | 3.88 | 0.61% |
Price Comparison
Compare SUNPHARMA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Sun Pharmaceutical Industries Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
ICICI Prudential Value Discovery Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5706% | Percentage of the fund’s portfolio invested in the stock 5.21% | Change in the portfolio weight of the stock over the last 3 months -0.28% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 8/93 (0) |
ICICI Prudential Bluechip Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4000% | Percentage of the fund’s portfolio invested in the stock 2.85% | Change in the portfolio weight of the stock over the last 3 months 0.28% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/82 (0) |
ICICI Prudential Equity & Debt Fund - Direct Plan - Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3595% | Percentage of the fund’s portfolio invested in the stock 4.11% | Change in the portfolio weight of the stock over the last 3 months 0.18% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 5/185 (+1) |
Compare 3-month MF holding change on Screener
smallcases
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Sun Pharmaceutical Industries Ltd
Events
Dividend Trend
Increasing Dividends
SUNPHARMA has increased dividends consistently over the last 5 years
Dividend Yield
Current dividend yield is 0.71%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹7.07 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 12, 2024
Dividend/Share
₹5.00
Ex DateEx Date
Jul 12, 2024
Cash Dividend
Ex DateEx DateFeb 9, 2024
Dividend/Share
₹8.50
Ex DateEx Date
Feb 9, 2024
Cash Dividend
Ex DateEx DateJul 28, 2023
Dividend/Share
₹4.00
Ex DateEx Date
Jul 28, 2023
Cash Dividend
Ex DateEx DateFeb 8, 2023
Dividend/Share
₹7.50
Ex DateEx Date
Feb 8, 2023
Cash Dividend
Ex DateEx DateAug 19, 2022
Dividend/Share
₹3.00
Ex DateEx Date
Aug 19, 2022
Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 28 October 2024Powered by Capital Market - Live
Sun Pharmaceutical Industries and Philogen S.p.A (Philogen) today announced that they have entered into a global licensing agreement for commercializing Philogen's specialty product, Fibromun (L19TNF). Fibromun, an innovative anti-cancer immunotherapy, is being investigated in registration trials by Philogen for the treatment of soft tissue sarcoma and glioblastoma. Under the terms of the agreement, Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun. Philogen will complete the ongoing pivotal clinical trials for the product, pursue Marketing Authorization with regulatory authorities, and manufacture commercial supplies. Sun Pharma will be responsible for commercialization activities. The two partner companies will share post-commercialization economics in about 45(Philogen):55(Sun Pharma) ratio. Other financial terms were not disclosed. Powered by Capital Market - Live
Philogen is an Italian-Swiss company active in the biotechnology sector, specialized in the research and development of pharmaceutical products for the treatment of highly lethal diseases. Fibromun, an innovative anti-cancer immunotherapy, is being investigated in registration trials by Philogen for the treatment of soft tissue sarcoma and glioblastoma. Under the terms of the agreement, Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun. Philogen will complete the ongoing pivotal clinical trials for the product, pursue marketing authorization with regulatory authorities, and manufacture commercial supplies. Sun Pharma will be responsible for commercialization activities. The two partner companies will share post-commercialization economics in about 45(Philogen)-to-55(Sun Pharma) ratio. Dilip Shanghvi, chairman and managing director of Sun Pharma, said: 'Fibromun's progress through development has been quite encouraging and it has potential to be an important option for treatment of soft-tissue sarcomas and other cancers with significant unmet medical needs. This partnership expands our clinical pipeline into oncology in alignment with our current portfolio in skin cancers. We keenly look forward to providing this treatment option globally in due course of time.' In May last year, Sun Pharma and Philogen entered into an exclusive distribution, license, and supply agreement for commercializing the specialty product Nidlegy in Europe, Australia and New Zealand. The first marketing authorization application for Nidlegy has been submitted to European Medicines Agency (EMA) for the treatment of locally advanced, fully resectable melanoma in the neoadjuvant setting. Sun Pharmaceuticals Industries is a leading global pharmaceutical company with specialty and generic presence and India's top pharma company. The company's consolidated net profit jumped 40.20% to Rs 2,835.6 crore on 5.96% rise in revenue from operations to Rs 12,652.75 crore in Q1 FY25 over Q1 FY24. The scrip shed 0.78% to currently trade at Rs 1911.30 on the BSE. Powered by Capital Market - Live
Sun Pharmaceutical Industries and Israel-based Moebius Medical announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to MM-II (Large Liposomes of DPPC and DMPC) for the treatment of osteoarthritis knee pain. Planning for confirmatory Phase 3 clinical trials for MMII is underway. The FDA's Fast Track program is designed to facilitate the development and expedite the review of therapies intended to treat serious conditions and address unmet medical needs in order to potentially bring important new medicines to patients earlier. Among other benefits, companies whose investigational products are granted FTD are eligible for more frequent interactions with the FDA during clinical development and potentially accelerated approval and/or priority review. 'As we enter Phase 3 development, we are very encouraged by the FDA's decision to grant Fast Track designation to MM-II and recognize its potential to fill an unmet medical need for patients suffering from Osteoarthritis,' said Marek Honczarenko, MD, PHD, Senior Vice President, Head Global Development at Sun Pharma.Powered by Capital Market - Live
MM-II is a novel non-opioid product that uses a proprietary suspension of large, empty, multilamellar liposomes which are intended to reduce friction and wear on the joint and thus relieve joint pain. The company and Moebius Medical jointly developing this product, have announced plans to initiate a Phase 3 clinical program and to seek a CE Mark for the product in the European Union. The FDA's Fast Track program is designed to facilitate the development and expedite the review of therapies intended to treat serious conditions and address unmet medical needs in order to potentially bring important new medicines to patients earlier. Among other benefits, companies whose investigational products are granted FTD are eligible for more frequent interactions with the FDA during clinical development and potentially accelerated approval and/or priority review. Marek Honczarenko, MD, PHD, senior vice president, Head Global Development, Sun Pharma, said, 'As we enter Phase 3 development, we are very encouraged by the FDA's decision to grant Fast Track designation to MM-II and recognize its potential to fill an unmet medical need for patients suffering from Osteoarthritis.' Moshe Weinstein, CEO of Moebius Medical, added, 'This Fast Track Designation, which will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II, and follows our recently released Phase 2b data, which showed MMII's potential to provide effective and durable treatment for patients with knee pain of Osteoarthritis.' Moebius Medical is a clinical stage biotechnology company that is developing novel pain relief treatments for osteoarthritis Sun Pharmaceuticals Industries is a leading global pharmaceutical company with specialty and generic presence and India's top pharma company. The company's consolidated net profit jumped 40.20% to Rs 2,835.6 crore on 5.96% rise in revenue from operations to Rs 12,652.75 crore in Q1 FY25 over Q1 FY24. The script rose 0.29% to Rs 1,825.75 on the BSE.Powered by Capital Market - Live
Sun Pharmaceutical Industries has launched Tedizolid Phosphate tablets 200 mg in India under the brand name 'STARIZO'. STARIZO (Tedizolid Phosphate) is a novel, oxazolidinone-class antibacterial, used to treat Acute Bacterial Skin and Skin Structure Infection (ABSSSI). Sun Pharma has obtained rights from Merck Sharp & Dohme Singapore Trading to develop, manufacture and commercialise Tedizolid Phosphate in India. Powered by Capital Market - Live
Sun Pharmaceuticals Industries Ltd gained for a fifth straight session today. The stock is quoting at Rs 1753.25, up 0.31% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.53% on the day, quoting at 24703.35. The Sensex is at 80851.87, up 0.53%. Sun Pharmaceuticals Industries Ltd has gained around 10.45% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceuticals Industries Ltd is a constituent, has gained around 7.94% in last one month and is currently quoting at 22237.85, up 0.19% on the day. The volume in the stock stood at 7.58 lakh shares today, compared to the daily average of 25.56 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1752.95, up 0.3% on the day. Sun Pharmaceuticals Industries Ltd is up 54.15% in last one year as compared to a 27.38% jump in NIFTY and a 45.31% jump in the Nifty Pharma index.The PE of the stock is 150.65 based on TTM earnings ending June 24.Powered by Capital Market - Live
Sun Pharmaceutical Industries has entered into an agreement with Pharmazz Inc. Delaware US, pursuant to which Sun Pharma has agreed to invest upto $15 Mn investment resulting in more than 5% holding in Pharmazz Inc. Pharmazz Inc (Pharmazz) is a Delaware, US corporation based in Willowbrook Illinois, US and is a biopharmaceutical company developing its two leading drug candidates, Sovateltide for treatment of acute cerebral ischemic stroke and Centhaquine for treatment of hypovolemic shock. Both products are approved in India and marketed through partners under brands, Tyvalzi (Sovateltide) and Lyfaquin (Centhaquine) and are being developed for USA and other markets. Sun Pharma shall also receive the exclusive right to license Sovateltide for marketing & distribution in certain emerging market countries. Powered by Capital Market - Live
Sun Pharmaceutical Industries Share Price Live Updates: Sun Pharma Closes at Rs 1720.35 with 8145 Shares Traded, 7-Day Avg Volume at 3,307,395 Shares - The Economic Times
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 10.64%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 13.71% to 13.23%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 29.15%, vs industry avg of 15.28%